Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin β-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

The present invention relates to a stabilized external preparation comprising thymosin beta 4 (Tβ4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of Tβ4. The preparation according to the present invention provides Tβ4 in a stable state by maintaining the biological activity of Tβ4 and minimizing the generation of Tβ4 sulfoxide through oxidization reactions and multimers through aggregation.

This disclosure provides methods for treating a SARS-CoV-2 infection in a subject comprising administering to the subject an effective amount of an inhibitor of COVID-induced RAS imbalance, that downregulates, for example, the Bradykinin system, the Renin-Angiotensin system, the hyaluronan synthesis pathway, or the fibrinogenesis pathway.

Provided herein are methods and compositions related to treating and preventing an age-related disease and inhibiting cell death using thymosin proteins.

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.

The present invention provides compositions and methods for improving cardiac function. Specifically, the present invention provides compositions and methods for treating a subject having a disorder or condition associated with aberrant cardiac tissue function, comprising contacting a patient having a disorder or condition associated with aberrant cardiac tissue function with a construct, or a construct associated with therapeutic cells, or a construct associated with fibroblast cells and therapeutic cells.

The present invention relates to a pharmaceutical composition for treating dry eye syndrome, which comprises Gly-Tβ4 as an active ingredient, and the pharmaceutical composition restores damaged corneal epithelial cells and also has an effect of proliferating goblet cells, and thus is effective for treating, preventing, or alleviating dry eye syndrome.

Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin β-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin β-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Methods, compositions and kits for treating autophagy mediated diseases and disorders are disclosed as well as methods of treating a subject suffering from chronic granulomatous disease (CGD) by administering an effective amount of a thymosin polypeptide or variant thereof to the subject.